New cancer therapy using genetically-engineered oncolytic Sendai virus vector.

Area of Science:

• Oncology
• Virology
• Gene Therapy

Background:

• Current gene therapy vectors face challenges in selective tumor targeting and efficient delivery.
• Sendai virus (SeV) based vectors offer potential for cancer treatment but require improved targeting mechanisms.

Purpose of the Study:

• To develop novel SeV-based gene transfer vectors for cancer therapy with enhanced tumor selectivity.
• To engineer SeV vectors that utilize tumor-specific proteases for cell-to-cell spreading and therapeutic payload delivery.

Main Methods:

• Modified SeV vectors were created lacking matrix genes for particle formation but retaining cell-to-cell spreading.
• Protease-cleavable sequences (MMP-cleavage or uPA-cleavage) were introduced into the SeV fusion gene for targeted activation.
• In vitro and in vivo studies were conducted using cancer cell lines (HT1080, PC-3) and xenograft models expressing specific proteases.

Main Results:

• MMP-targeted SeV vectors induced syncytia formation in MMP-expressing HT1080 cells and inhibited tumor growth in vivo.
• uPA-targeted SeV vectors demonstrated similar anti-tumor effects in uPA-expressing PC-3 cells.
• Significant apoptosis was observed in the fused tumor cells, confirming vector-mediated cell death.

Conclusions:

• Redesigned SeV vectors exhibit protease-dependent, controllable cell-to-cell spreading, enabling selective tumor targeting.
• These vectors demonstrate significant antitumor efficacy in solid tumors through targeted delivery and induction of apoptosis.
• Recombinant SeV technology holds promise for selective tumor targeting and eradication in cancer therapy.